Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verastem

6.21
+0.47008.19%
Volume:1.02M
Turnover:6.18M
Market Cap:319.75M
PE:-1.70
High:6.28
Open:5.70
Low:5.70
Close:5.74
Loading ...

Verastem Shares Soar on FDA Priority Review of Cancer Treatment

Dow Jones
·
01 Jan

Sector Update: Health Care Stocks Lower in Afternoon Trading

MT Newswires Live
·
01 Jan

US Equity Indexes Decline After Midday Tuesday as 2024 Draws to Close

MT Newswires Live
·
01 Jan

Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application

GuruFocus.com
·
31 Dec 2024

Verastem Shares up 32% After FDA Grants Priority Review for Ovarian Cancer Combo Therapy

THOMSON REUTERS
·
31 Dec 2024

Traders Cautious as 2024 Draws to Close, Stifling US Equity Futures Pre-Bell

MT Newswires Live
·
31 Dec 2024

Morning Movers: EHang jumps following guidance raise

TIPRANKS
·
31 Dec 2024

Verastem Shares up 27.5% Premarket After FDA Grants Priority Review for Ovarian Cancer Combo Therapy

THOMSON REUTERS
·
31 Dec 2024

Top Premarket Gainers

MT Newswires Live
·
31 Dec 2024

BUZZ-Verastem jumps as FDA grants priority review for ovarian cancer combo therapy

Reuters
·
31 Dec 2024

BTIG Raises Price Target on Verastem to $20 From $13, Keeps Buy Rating

MT Newswires Live
·
31 Dec 2024

Verastem price target raised to $20 from $13 at BTIG

TIPRANKS
·
31 Dec 2024

U.S. RESEARCH ROUNDUP- Axsome Therapeutics, Ducommun, Vacasa

Reuters
·
31 Dec 2024

Verastem Inc : Btig Raises Target Price to $20 From $13

THOMSON REUTERS
·
31 Dec 2024

Verastem Oncology's New Cancer Treatment Gets FDA Priority Review

Dow Jones
·
31 Dec 2024

Verastem's Ovarian Cancer Drug Application Accepted by FDA, Gets Priority Review

MT Newswires Live
·
31 Dec 2024

BRIEF-Verastem Oncology Announces FDA Acceptance And Priority Review Of New Drug Application For Avutometinib In Combination With Defactinib For The Treatment Of Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer

Reuters
·
31 Dec 2024

Verastem announces FDA acceptance and Priority Review of NDA for Avutometinib

TIPRANKS
·
31 Dec 2024

Verastem jumps 50% to $5.50 on FDA priority review for Avutometinib

TIPRANKS
·
31 Dec 2024

Verastem Inc - Pdufa Target Action Date Set for June 30, 2025

THOMSON REUTERS
·
31 Dec 2024